|
|
FOR IMMEDIATE RELEASE
Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc.
508-359-4005, x108
Pico-Tesla achieves significant regulatory milestone
Company receives ISO 13485:2003 Quality Management System certification
“This event represents another big step for us toward establishing the
clinical application of Magneceutical® Therapy.” -Allen Braswell, CEO, Pico-Tesla
LITTLETON, Colo., March 14, 2011 —Pico-Tesla, The Magneceutical® Company, has
received the International Organization for Standardization (ISO) 13485:2003 certificate for the
“design, development, production, manufacture and distribution of resonator systems that
generate a low-level electromagnetic field for the therapeutic treatment of disease.”
ISO 13485:2003 specifies requirements for a Quality Management System whereby a company
must demonstrate its ability to provide medical devices and related services that consistently meet
the highest quality standards related to the clinical needs of patients and healthcare providers. The
certification satisfies Health Canada as a pre-requisite for medical device distribution into
Canada, and is also aligned to meet the requirements to the European Medical Device Directive
(MDD) 93/42/EEC as amended by 2007/47/EC, to place the CE mark on its products. The
certification is a significant step in Pico-Tesla demonstrating conformance to medical device
safety and effectiveness requirements, thus strengthening the Company’s ability to enter
worldwide markets.
“Receiving the ISO 13485 certification bears strong witness to the significant progress we are
making toward establishing the clinical application of Magneceutical® Therapy for Parkinson’s
and other difficult-to-treat diseases,” said Allen Braswell, CEO of Pico-Tesla.
“There is one thing that has stayed in my mind since getting involved with this opportunity. That
is, to be so driven and committed to quality in such early stages of your product development is
not a typical behavior of many companies, whether they are big or small. That commitment
driven from the top can only bring continued success!” said Lynette Makowski, Principal
Consultant, Achieving RA/QA Compliance LLC, a Regulatory and Quality Expert in the Medical
Device Industry.
“There is no cure for Parkinson’s disease,” said Allen Braswell, president and CEO of Pico-Tesla.
“However, early clinical data such as those produced by this pilot study strongly suggest that our Magneceutical™ Therapy may improve both motor and non-motor symptoms of PD. Therefore
we are extremely excited to continue with the clinical development of Magneceutical™ Therapy.”
Pico-Tesla’s Magneceutical® Therapy is currently in clinical trials to determine its effectiveness
for improving the signs and symptoms of several diseases, including Parkinson’s disease, atrial
fibrillation, Alzheimer’s disease, fibromyalgia and osteoarthritis.
Privately held Pico-Tesla Magnetic Therapies is an emerging medical technology company with
operations at: 4700 140th
Avenue North, Suite #101, Clearwater, FL 33762; and, 27780 Novi Road, Suite 100, Novi,
MI 48377 (248) 773-8969.
CAUTION: The Resonator™ device is an Investigational Device limited by federal (or United
States) law to investigational use. The Resonator™ device is not for sale, nor is the
Magneceutical™ Therapy generally available outside of Investigational Review Board (IRB)-
approved clinical studies.
|